SI Figure S3. Evaluation of the body weight of PF-2771 treated mice. (A) In the basal patient-derived xenograft model PDX-AA1077, 100 mg/kg QD PF-2771 (■) was well-tolerated relative to vehicle control animals (○). (B) HCC1599 basal-like breast cancer tumor model evaluation of 100 mg/kg QD PF-2771 (■), vehicle (□), 25 mg/kg/week docetaxel (Δ), and 20 mg/kg twice weekly paclitaxel (▲). (C) Body weight analysis of PF-2771 in HCC1806 xenograft model. SCID mice were treated with vehicle (□), 3 (Δ), 10 (○), 30 (▲) mg/kg of PF-2771 once daily for 14 days. SCID mice were treated with 100 mg/kg (■) of PF-2771 with the following schedule: once daily or with vehicle for 4 days, 3 day dosing holiday, another 4 day dosing cycle.

A.



B.



C


Murine Body Weight HCC1806 Model (g)
25
20
15
10
5
0
0
2
4
6
8
10
12
14
16
Days of Treatment
vehicle
PF-2771 3mpk
PF-2771 10mpk
PF-2771 30mpk
PF-2771 100mpk